Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CUPH | ISIN: US09077A1060 | Ticker-Symbol:
NASDAQ
26.06.25 | 22:00
1,990 US-Dollar
+2,58 % +0,050
1-Jahres-Chart
BIOMEA FUSION INC Chart 1 Jahr
5-Tage-Chart
BIOMEA FUSION INC 5-Tage-Chart

Aktuelle News zur BIOMEA FUSION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBiomea Fusion stock price target cut to $4 from $18 at H.C. Wainwright1
MoBiomea Fusion, Inc.: Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)3
20.06.Biomea Fusion, Inc. - 8-K, Current Report1
18.06.Biomea Fusion stock falls after announcing public offering2
18.06.Biomea Fusion sinks 25%, prices $40M stock offering3
18.06.Biomea Fusion, Inc.: Biomea Fusion Announces Pricing of Public Offering of Securities2
17.06.Biomea Fusion launches public offering of common stock and warrants2
17.06.Biomea Fusion launches public offering of stock and warrants; shares down 23%2
BIOMEA FUSION Aktie jetzt für 0€ handeln
17.06.Biomea Fusion, Inc.: Biomea Fusion Announces Proposed Public Offering of Securities2
16.06.Biomea Fusion stock rating reiterated at Buy by H.C. Wainwright3
13.06.Biomea Fusion, Inc. - 8-K, Current Report1
13.06.Biomea Fusion reports sustained responses in leukemia patients1
13.06.Biomea Fusion, Inc.: Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 20253
06.05.Biomea Fusion stock target cut to $18 by H.C. Wainwright13
05.05.Biomea Fusion, Inc. - 10-Q, Quarterly Report5
05.05.Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights211Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients...
► Artikel lesen
05.05.Biomea Fusion, Inc. - 8-K, Current Report2
01.04.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)238REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that...
► Artikel lesen
31.03.Biomea Fusion, Inc. - 10-K, Annual Report4
31.03.Biomea Fusion, Inc.: Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights134Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated...
► Artikel lesen
Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1